Simon Lord

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Harris BHL, Di Giovannantonio M, Zhang P, et al. (2024) New role of fat-free mass in cancer risk linked with genetic predisposition. Scientific Reports. 14: 7270
Clift AK, Collins GS, Lord S, et al. (2023) Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study. The Lancet. Digital Health. 5: e571-e581
Coombes RC, Howell S, Lord SR, et al. (2023) Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4741
Charles Coombes R, Howell S, Lord SR, et al. (2023) Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4444
Carroll TM, Chadwick JA, Owen RP, et al. (2023) Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell. 41: 1222-1241.e7
Clift AK, Dodwell D, Lord S, et al. (2023) Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study. Bmj (Clinical Research Ed.). 381: e073800
Lord SR, Harris AL. (2023) Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer
Skolariki A, D'Costa J, Little M, et al. (2022) Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-Tumor Therapy. 3: 172-199
Harris BHL, Macaulay VM, Harris DA, et al. (2022) Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Reviews
Telli ML, Tolaney SM, Shapiro GI, et al. (2022) Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj Breast Cancer. 8: 45